November 6, 2025
Photo Credit: Dreamstime Photos
DEL MAR, Calif. — Sydnexis‘ partner Santen has announced that the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ryjunea (low‑dose atropine 0.1 mg/ml). It is the first MHRA‑approved treatment in the U.K. to slow myopia progression in children aged 3–14 years who progress by ≥0.50D per year and have refractive errors between −0.50D and −6.00D.
This approval comes after authorization by the European Commission and the initial launch in Germany earlier this year. Sydnexis’ low-dose atropine eye drop SYD-101 is licensed to Santen in Europe, the Middle East and Africa, which Santen commercializes under the brand name Ryjunea. Santen is a global pharmaceutical company with over 135 years of experience dedicated to advancing eye health and improving lives through better vision.
“We are thrilled that the MHRA has granted approval of Ryjunea to Santen, marking another important milestone in bringing this innovative therapy to even more patients in need,” said Perry Sternberg, Chief Executive Officer of Sydnexis. “Backed by the global STAR study, this announcement underscores the potential of an approved low-dose atropine solution to address a significant unmet medical need for children with progressive myopia worldwide.”
